Moderna Inc (MRNA)vsMetaVia Inc. (MTVA)
MRNA
Moderna Inc
$142.77
-4.60%
HEALTHCARE · Cap: $57.00B
MTVA
MetaVia Inc.
$1.66
-1.19%
HEALTHCARE · Cap: $7.38M
Smart Verdict
WallStSmart Research — data-driven comparison
MTVA leads profitability with a 0.0% profit margin vs -141.4%. MTVA earns a higher WallStSmart Score of 23/100 (F).
MRNA
Avoid21
out of 100
Grade: F
MTVA
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$135.25
Current Price
$142.77
$7.52 discount
Intrinsic value data unavailable for MTVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : MTVA
The strongest argument for MTVA centers on Price/Book, Debt/Equity.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : MTVA
The primary concerns for MTVA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while MTVA is a value play — different risk/reward profiles.
MTVA carries more volatility with a beta of 0.90 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MTVA generates stronger free cash flow (-4M), providing more financial flexibility.
Bottom Line
MTVA scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
MetaVia Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MetaVia Inc. is an innovative technology company dedicated to delivering advanced digital solutions that enhance connectivity and productivity across multiple sectors. Leveraging cutting-edge artificial intelligence and cloud computing technologies, MetaVia crafts tailored platforms that address complex client challenges, positioning itself as a leader in the industry. The firm's commitment to sustainability and social responsibility not only aligns with current market needs but also underscores its long-term growth strategy. As MetaVia navigates the dynamic tech landscape, it is well-placed to generate significant value for shareholders.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?